HUTCHMED (NASDAQ:HCM) Issues Quarterly Earnings Results, Misses Estimates By $0.09 EPS

HUTCHMED (NASDAQ:HCM) announced its quarterly earnings data on Thursday. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.09), FiscalAI reports. The company had revenue of $139.14 million for the quarter, compared to the consensus estimate of $304.16 million.

Here are the key takeaways from HUTCHMED’s conference call:

• Oncology revenue rose 23% to $162 million in the first half of 2026, supported by strong China sales of ELUNATE and SULANDA and 40% growth in FRUZAQLA global in-market sales. Management maintained its full-year revenue guidance.
• FRUZAQLA’s ex-U.S. geographic expansion drove particularly strong momentum, with sales up 70% outside the U.S.; management expects further growth as additional countries launch the product and secure reimbursement.
• The company reported $16 million of net income and a substantial cash reserve of $1.4 billion, while reiterating its commitment to remain broadly breakeven or profitable as it increases investment in growth programs.
• HUTCHMED advanced its pipeline, with two ATTC assets in global Phase I trials and a third cleared for clinical development. Key savolitinib readouts from the global SAFFRON and China SANOVO studies are expected in the second half, while ATTC clinical data are anticipated in 2027.
• R&D spending increased to $79 million from $72 million as the company invested in ATTC trials, discovery capabilities and AI. Its non-core, low-margin Other Ventures distribution business declined by nearly 20% on a constant-currency basis, partly due to expanded Chinese volume-based procurement.

HUTCHMED Stock Down 5.4%

NASDAQ:HCM traded down $0.62 during mid-day trading on Thursday, reaching $10.77. The company’s stock had a trading volume of 59,676 shares, compared to its average volume of 47,249. The company has a quick ratio of 4.83, a current ratio of 4.96 and a debt-to-equity ratio of 0.05. HUTCHMED has a 1 year low of $9.77 and a 1 year high of $18.30. The stock has a fifty day moving average of $11.02 and a 200-day moving average of $13.23.

Institutional Investors Weigh In On HUTCHMED

Several large investors have recently modified their holdings of the business. State Street Corp lifted its position in shares of HUTCHMED by 1.2% in the 4th quarter. State Street Corp now owns 321,305 shares of the company’s stock worth $4,283,000 after purchasing an additional 3,801 shares during the period. M&G PLC increased its holdings in HUTCHMED by 26.7% during the fourth quarter. M&G PLC now owns 259,033 shares of the company’s stock valued at $3,367,000 after buying an additional 54,601 shares during the period. Amundi raised its stake in HUTCHMED by 41.9% in the third quarter. Amundi now owns 223,330 shares of the company’s stock worth $3,620,000 after buying an additional 65,898 shares in the last quarter. Jane Street Group LLC raised its stake in HUTCHMED by 128.0% in the first quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock worth $3,343,000 after buying an additional 124,771 shares in the last quarter. Finally, UBS Group AG raised its stake in HUTCHMED by 112.8% in the third quarter. UBS Group AG now owns 137,000 shares of the company’s stock worth $2,158,000 after buying an additional 72,614 shares in the last quarter. Institutional investors own 8.82% of the company’s stock.

Analysts Set New Price Targets

HCM has been the topic of a number of research analyst reports. The Goldman Sachs Group dropped their target price on shares of HUTCHMED from $16.00 to $14.00 and set a “neutral” rating on the stock in a research note on Thursday, July 23rd. Morgan Stanley set a $13.60 price target on shares of HUTCHMED in a research note on Thursday, May 28th. Bank of America lowered their price target on HUTCHMED from $20.00 to $17.00 and set a “buy” rating for the company in a report on Tuesday, July 7th. Finally, Weiss Ratings raised HUTCHMED from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $14.87.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.